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822-4 Which Features of the Metabolic Syndrome Predict 
Clinical Outcomes (DeathlMyocardial Infarction) in 
Patients With Angiographic Coronary Artery Disease? 
Heath U. Jones, Joseph 6. Muhlestein, John F. Carlquist, Benjamin D. Home, Robert R. 
Pearson, Chloe A. Allen Maycock, Sandra P. Reyna, Tami L. Bair. Donald L. LappO, Dale 
G. Renlund, Jeffrey L. Anderson, LDS Hospital, Salt Lake City, UT, University of Utah. 
Salt Lake City, UT 
Background: The metabolic syndrome (MS), a clustering of dyslipidemia, dysglycemia, 
hypertension, and obesity, IS regarded as an important risk factor for coronary arlery dis- 
ease (CAD) onset. The Adult Treatment Panel III recently provided a uniform definition of 
MS, but the predictive value (PV) of MS and its components for cardiovascular events 
once CAD has developed is unknown. 
Methods: We prospectively tested the PV of MS and its components for incident death or 
myocardial infarction (D/Ml) !n patients (pts) with advanced CAD (z-70% stenosis). Acute 
Ml at presentation was excluded. Components of the MS assessed at baseline included: 
1) fasting glucose (FG) 2110 mg/dL, 2) triglycerides (TG) 2150 mg/dL, 3) high density 
lipoprotein (HDL) ~40 mg/dL in men or ~50 mg/dL in women), and 4) systolic blood pres- 
sure (SBP) 2130 and/or diastolic BP s5 mmHg. MS was defined as 23 features. Waist 
measurement was not available, but body mass index (BMI z27 kg/mZ) was explored as 
a surrogate measure. Analysis used multivariable Cox regression. 
Resub: The study cohort was 2,037 pts; 76% were male; average age was 65~11 y; 
17% had a prior Ml and 8% had heart failure (HF). MS was present in 51% (high FG: 
45%, high TG: 53%, low HDL: 74%, high S/DBP: 77%). High BMI was present in 57%. In 
contrast to our pnor finding that MS predicts CAD diagnosis, MS failed to predict D/MI in 
pts with existing CAD (p=O.61). Only high FG , a MS component, predlcted D/MI (hazard 
ratio [HR] 1.41, 95% Cl 1.14-1.74, p=O.O02). (Clinical diagnosis of diabetes was even 
better than FG: HR 1.92, p<O.OOl). High TG, low HDL, and high S/DBP were not predic- 
tors (p=O.2-0.3). LIkewise, high BMI did not predict risk. In multivariable modeling. D/MI 
was predicted by age (p<O OOl), high FG (HR=1.36, Cl 1.12-l .71, p=O 003), and high S/ 
DBP (HR=0.72. Cl 0.57-0.91, p=O.O06). (The PV of S/DBP disappeared when pts with 
HF and prior Ml were excluded). 
Conclusion: Once CAD is established, high FG alone, but not MS, dtstingulshes subse- 
quent prognosis (D/Ml). This extends previous observations of reduced PV for several 
established risk factors (e.g., gender, hyperlipidemia, smoking, hypertension. but not dia- 
betes) when applied to secondary as compared to primary risk assessment 
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grade stenosis 24 hours after successful flbrinolysis are at increased risk for death and 
reinfarction, and -with It- the potential benefit of a routine invasive strategy. 
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822-3 Six-Month Mortality Rates Are Lower in Patients With an 
Acute Coronary Syndrome Treated With the 
Combination of Clopidogrel and a Statin Than in 
Patients Treated With Either Therapy Alone: An 
Analysis From the Global Registry of Acute Coronary 
Events 
Michael J. Lim Frederick A. Spencer, Joel M. Gore, Omar H. Dabbous, Eva M. Kline- 
Rogers, Roben J. Goldberg, Donna DiBenedeno, Kim A. Eagle, Rajendra H. Mehta, on 
behalf of the GRACE Investigators, University of Michigan Health System, Ann Arbor, MI, 
University of Massachusetts Medical School, Worcester. MA 
Background: The use of clopidogrel as well as statins has been shown to prevent recur- 
rent adverse events in patients with acute coronary syndromes. However, recent in-vitro 
data suggest that the antiplatelet effects of clopidogrel may be mitigated by the concomi- 
tant use of a statin. We hypothesized that, if these drug interactions are clinically rele- 
vant, then the mortality reduchon in patients receiving both of these agents would not be 
as great. 
Methods: Utilizing the GRACE database, 6.month mortality and stroke were evaluated 
in 4 groups based on discharge treatments: Group I=asplnn (ASA) alone (n=2956), 
Group Il=ASA+clopidogrel (n=670), Group Ill=ASA+statin (n=2557), and Group IV= 
ASA+statin+clopidogrel (n=l229). 
Results: Overall mortality for the patients treated with aspinn was 7.2%, compared to 
4.8% in Group II, 4.2% in Group Ill, and 3.0% in Group IV. There was a trend toward 
reduced stroke rate with combination therapy(l.3%. 1.7%. 1.2% and 0.7% respectively). 
Utilizing a Cox regrewon model, hazard ratios and 95% confidence limits were com- 
puted for mortality at 6 months compared to treatment with aspirin alone (Fig). 
Conclusions: These data suaaest that. if there is a oharmacolooic inter&ion between _- 
statln medications and clopidogrel, it is not apparent in B-month mortality rates within the 
GRACE reaistw oatients. In fact. there is a trend toward reduced’mortalitv in those _ ,. 
patients receiving aspirin+clopidogrel+statin compared lo the other groups, suggesting a 
synergistic effect. 
822-5 Clinical and Angiographic Predictors of Cardiac Events 
in Patients With Non-ST Elevation Acute Coronary 
Syndromes Undergoing Percutaneous Coronary 
Intervention in the Current Era: Insights From the 
PRESTO Trial 
Heidar Ariomand, James T. Willerson, David R. Holmes, Bassam Roukoz, Satish 
Surabhi, lsmail Dairy-&a, Chowdhury Ahsan, Marc Cohen, Zoltan G. Turi, Sheldon 
Goldberg, Drexel Universliy College of Medicine, Philadelphia, PA, Mayo Clinic, 
Rochester, MN 
Background: Patients with non-ST elevation acute coronary syndromes (NSTE-ACS) 
represent a high-risk group of patients An early invasive strategy with percutaneous cor- 
onary intervention (PCI) is recommended in these patients. However, there is limited 
data on predictors of outcome in ACS patients undergoing PCI in the current era. 
Methods: We identified clinical and angiographic predictors of outcome in 5,503 consec- 
utive patients with NSTE-ACS who underwent PCI between April 1999 and July 2000 as 
a part of the Prevention of Restenosis with Tranllast and its Outcomes (PRESTO) tnal. 
Results: At g-month follow-up, 18.4% of pattents experienced a cardiac event (death, 
MI, or TVR). Multivariate analysis identified several clinical and angiographic predictors 
of a cardiac event (Table). 
Conclusions: In patients with ACS undergoing PCI, certain clinical characteristics and 
angiographic features predict a high risk of adverse outcome. 
Table 1 Clinical and Anglographx Prcdmxs of Cardiac Evcnta at 9 month, 
Clinical Variables: 
- Diabetes 
- Prior CABG 
- Prior PCI 
Angiographic Variables: 
_ Bifurcation Iwon 
- Multivessel CAD 
- Restenotic lesion 
- Ostial Iwon 
Odds ratio (95% Cl) 
p-value 
1.34(1.15-1.56) < 0.01 
1.35 (1.12-1.62) < 0.01 
1.39 (1.15-1.68) < 0.01 
1.33 (1.06-I .67) 0.01 
1.51 (1.06215) 0.02 
1.58 (1.27-1.98) < 0.01 
1.74 (1.38-2.19) < 0.01 
